Neupogen G-CSF data

AMGN (Thousand Oaks, Calif.) announced that preliminary analysis of a Phase III trial of G-CSF in combination with standard antibiotic therapy in 756 patients did not give significant differences on the primary outcome of time to resolution of morbidity.

A subset of patients in the Phase III trial with more severe pneumonia showed a difference in mortality, duplicating a result seen in a Phase I/II study. AMGN said it will seek to confirm this benefit in a new Phase III trial starting this winter. ...